

SAKK presentations at ASCO 2024

SAKK trials

Trial: SAKK 96/12

Title: Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w)

Speaker: Roger von Moos

Type of presentation: Poster

Abstract #: 12067

Poster Bd #: 196

Session name: Symptom Science and Palliative Care

Location: Hall A

Time: June 3, 2024, 1:30 PM – 4:30 PM CDT

Link: <https://meetings.asco.org/abstracts-presentations/231323>

Trial: SAKK 75/08

Title: Whole transcriptome analysis to reveal epithelial-mesenchymal transition after neoadjuvant therapy with or without additional anti-EGFR treatment: Subgroup analysis of esophageal squamous cell carcinomas of the SAKK 75/08 and the EORTC AIO POWER study

Speaker: Alexander Siebenhuener

Type of presentation: Poster

Abstract #: 4071

Poster Bd #: 51

Session name: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Location: Hall A

Time: June 1, 2024, 1:30 PM – 4:30 PM CDT

Link: <https://meetings.asco.org/abstracts-presentations/234256>

Intergroup

Trial: HD21

Title: Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSB HD21, a randomized study

Speaker: Peter Borchmann

Type of presentation: Oral presentation

Abstract #: LBA7000

Session name: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Location: S100bc

Time: June 1, 2024, 3:00 PM – 6:00 PM CDT

Link: <https://meetings.asco.org/abstracts-presentations/231057>

Trial: AGO-OVAR 2.29/ENGOT-ov34

Title: Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study

Speaker: Frederik Marmé

Type of presentation: Oral presentation

Abstract #: LBA5501

Session name: Gynecologic Cancer

Location: Hall D2

Time: June 2, 2024, 8:00 AM – 11:00 AM CDT

Link: <https://meetings.asco.org/abstracts-presentations/231703>

Trial: ETOP BEAT-meso / ETOP 13-18

Title: BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial

Speaker: Sanjay Popat

Type of presentation: Oral presentation

Abstract #: LBA8002

Session name: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Location: Arie Crown Theater

Time: June 3, 2024, 8:00 AM – 11:00 AM CDT

Link: <https://meetings.asco.org/abstracts-presentations/232345>

Trial: DANTE

Title: A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK

Speaker: Salah-Eddin Al-Batran

Type of presentation: Poster

Abstract #: TPS4184

Poster Bd #: 162a

Session name: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Location: Hall A

Time: June 1, 2024, 1:30 PM – 4:30 PM CDT

Link: <https://meetings.asco.org/abstracts-presentations/238415>

Trial: OPBC-03/SAKK 23/16/IBCSG 57-18/ABCSG-53/GBG-101-TAXIS

Title: Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (OPBC-03/SAKK 23/16/IBCSG 57-18/ABCSG-53/GBG-101-TAXIS)

Speaker: Walter Paul Weber

Type of presentation: Poster

Abstract #: TPS611

Poster Bd #: 203a

Session name: Breast Cancer—Local/Regional/Adjuvant

Location: Hall A

Time: June 2, 2024, 9:00 AM – 12:00 PM CDT

Link: <https://meetings.asco.org/abstracts-presentations/239694>